Review of the Safety and Feasibility of Rapid Infusion of Rituximab
Author:
- 1 March 2010
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 6 (2) , 91-93
Abstract
Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.Keywords
This publication has 20 references indexed in Scilit:
- Rapid infusion of rituximab over 60 minEuropean Journal of Haematology, 2009
- A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac FunctionClinical Cancer Research, 2008
- Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody TherapyThe Oncologist, 2008
- A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's LymphomaAnnual Review of Medicine, 2008
- Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community settingBlood, 2007
- Rapid infusion of rituximab with or without steroid‐containing chemotherapy: 1‐yr experience in a single institutionEuropean Journal of Haematology, 2006
- Rapid-infusion rituximab in lymphoma treatmentAnnals of Oncology, 2005
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002